Published in
Oxford University Press (OUP), Journal of the National Cancer Institute, 2(108), p. djv310
DOI: 10.1093/jnci/djv310
Links
- ORCID
- ORCID
- ORCID
- ORCID
- Oxford University Press (OUP)
- [www.researchgate.net] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
Tools
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy
,
Amaro Taylor-Weiner,
Naema Nayyar,
David J. Panka,
Ryan J. Sullivan,
Dennie T. Frederick,
Malak Abedalthagafi,
Pamela S. Jones,
Ian F. Dunn,
Brian V. Nahed ,
Daniel P. Cahill†,
Javier M. Romero ,
David N. Louis
and other authors.
Full text: Download
Abstract
We recently reported that BRAF V600E is the principal oncogenic driver of papillary craniopharyngioma, a highly morbid intracranial tumor commonly refractory to treatment. Here, we describe our treatment of a man age 39 years with multiply recurrent BRAF V600E craniopharyngioma using dabrafenib (150 mg, orally twice daily) and trametinib (2 mg, orally twice daily). After 35 days of treatment, tumor volume was reduced by 85%. Mutations that commonly mediate resistance to MAPK pathway inhibition were not detected in a post-treatment sample by whole exome sequencing. A blood-based BRAF V600E assay detected circulating BRAF V600E in the patient’s blood. Re-evaluation of the existing management paradigms for craniopharyngioma is warranted, as patient morbidity might be reduced by noninvasive mutation testing and neoadjuvant-targeted treatment.